The company has repaid approximately $209 million in debt in the first half of FY22 as compared to debt as of March 31, 2021.
Sun Pharmaceutical Industries Ltd reported a 29% increase in consolidated net profit at Rs 2,047 crore for the second quarter as against adjusted net profit in the year-ago period. Gross sales grew 13% year-on-year to ₹9,557 crore.
India sales of ₹3,188 crore were up 26% over the same quarter last year and US-end dosage sales grew 8% to $361 million compared to Q2 last year.
Managing Director Dilip Shanghvi said, “Following our good Q1 performance, we have maintained the positive momentum in Q2, with annual growth of 13%, driven by broad-based growth across multiple geographies.”
“Our global specialty business grew 43% compared to Q2 last year. Ilumya has grown both yoy and gradual. Our India business is performing well with 26% year-on-year growth. We are determined to remain focused on growing our overall business as well as strengthening our global specialty portfolio. The recent launch of Vinlevi in the US and Illumya in Canada is a step forward in this direction.
The company has repaid approximately $209 million in debt in the first half of FY22 as compared to debt as of March 31, 2021. With this loan repayment, Sun Pharma had approximately $200 million in net cash as of September 30, 2021. -Taro base.
Taro reported sales of $132 million in the second quarter of fiscal 2012, down about 8% year-over-year, and adjusted net profit of approximately $25 million, up 45% compared to the second quarter of last year. is less.
.